News
FDA delays decision on Sanofi's subcutaneous Sarclisa
The FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.
News
MSD, Eisai report setback in first-line kidney cancer trial
The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.
News
Jazz and Lilly cancer drugs cleared for use by NHS
Jazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.
Oncology
From promise to practice: What must happen next for genetic ...
The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.
News
Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia
Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
